The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
GLUT1 reductions exacerbate Alzheimer's disease vasculo-neuronal dysfunction and degeneration
Open accessAbstract
The glucose transporter GLUT1 at the blood-brain barrier (BBB) mediates glucose transport into the brain. Alzheimer's disease is characterized by early reductions in glucose transport associated with diminished GLUT1 expression at the BBB. Whether GLUT1 reduction influences disease pathogenesis remains, however, elusive. Here we show that GLUT1 deficiency in mice overexpressing amyloid β-peptide (Aβ) precursor protein leads to early cerebral microvascular degeneration, blood flow reductions and dysregulation and BBB breakdown, and to accelerated amyloid β-peptide (Aβ) pathology, reduced Aβ clearance, diminished neuronal activity, behavioral deficits, and progressive neuronal loss and neurodegeneration that develop after initial cerebrovascular degenerative changes. We also show that GLUT1 deficiency in endothelium, but not in astrocytes, initiates the vascular phenotype as shown by BBB breakdown. Thus, reduced BBB GLUT1 expression worsens Alzheimer's disease cerebrovascular degeneration, neuropathology and cognitive function, suggesting that GLUT1 may represent a therapeutic target for Alzheimer's disease vasculo-neuronal dysfunction and degeneration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The Slc2a1 + / -mice with haploid deficiency in glucose transporter GLUT1 in brain endothelial cells develop microvascular reductions with BBB breakdown including loss of TJ and basement membrane proteins (649), whereas knockout of murine Mfsd2a gene results in not only diminished brain uptake of docosahexaenoic acid (DHA) in the form of lysophosphatidylcholine, but also leads to dysregulated cave”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [649]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Since glucose concentration is lower in the brain interstitial fluid (ISF) compared with plasma, GLUT1 favors blood-to-brain transport of circulating glucose (141, 390, 649).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [649]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Glut1 + / -mice phenocopy human pathology, and develop initially within 2-3 wk of age BBB breakdown with loss of tight junctions and diminished glucose uptake by the brain, which is followed by microvascular regression, reduced brain perfusion and development of secondary neurodegenerative changes, microcephaly, and loss of cortical and hippocampal neurons (649).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [649]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Experimental studies also support diminished transport of 14 C-labeled glucose across the BBB in haploinsufficient Slc2a1 + / -mice lacking ~50% copies of the GLUT1 BBB transporter (649).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [649]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Reduced activity and expression of the GLUT-1 transporter in the BBB suggest decreased glucose uptake and utilization by the brain,360,363 which may further exacerbate cerebrovascular degeneration, BBB breakdown, and Aβ pathology in models overexpressing APP, inducing neurodegeneration and cognitive deficits (Fig. 4).364”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [364]
The cited source says what the claim attributes to it.
In the citing paper
“reduced GLUT1 levels may also inhibit LRP1 transcriptionally via sterol regulatory element binding protein 2 (SREBP2) (649).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [649]
The cited source says what the claim attributes to it.
In the citing paper
“Brain endothelial specific or enriched transporters are often indispensable for BBB barriergenesis, as for example, the glucose transporter-1 (GLUT1) (649), sodium-dependent lysophosphatidylcholine (LPC) symporter, the major facilitator superfamily (MFS) domain-containing protein 2a (MFSD2A) (62), and monocarboxylic acid transporter MCT8 (611).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [649]
The cited source says what the claim attributes to it.
In the citing paper
“Since glucose concentration is lower in the brain interstitial fluid (ISF) compared with plasma, GLUT1 favors blood-to-brain transport of circulating glucose (141, 390, 649).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [649]
The cited source says what the claim attributes to it.
In the citing paper
“GLUT1 is expressed in endothelial cells, but not in neurons (141, 649).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [649]
The cited source says what the claim attributes to it.
In the citing paper
“For example, LRP1 minigene delivery to the BBB by viral vectors facilitates A 𝛃 clearance and attenuates A 𝛃 pathology (649).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [649]
The cited source says what the claim attributes to it.
In the citing paper
“which we know leads to severe neurological phenotype in the GLUT1-deficiency syndrome (630, 649).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [649]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: Pericyte loss influences Alzheimer-like neurodegeneration in mice
Sagare, A. P., Bell, R. D., Zhao, Z., Ma, Q., Winkler, E. A., Ramanathan, A., & Zlokovic, B. V. (2013) · Nature Communications · doi:10.1038/ncomms3932 · Cited by 589
Self-citationRetractedCorrelative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210
The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280
Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders
Zlokovic, B. V. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3114 · Cited by 2,969
Bell, R. D., Winkler, E. A., Sagare, A. P., Singh, I., LaRue, B., Deane, R., & Zlokovic, B. V. (2010) · Neuron · doi:10.1016/j.neuron.2010.09.043 · Cited by 1,448
Self-citationRAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain
Deane, R., Du Yan, S., Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., Welch, D., Manness, L., Lin, C., Yu, J., et al. (2003) · Nature Medicine · doi:10.1038/nm890 · Cited by 1,426
Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413
Apolipoprotein E controls cerebrovascular integrity via cyclophilin A
Bell, R. D., Winkler, E. A., Singh, I., Sagare, A. P., Deane, R., Wu, Z., Holtzman, D. M., Betsholtz, C., Armulik, A., Sallstrom, J., et al. (2012) · Nature · doi:10.1038/nature11087 · Cited by 1,293
Self-citationAssessing nest building in mice
Deacon, R. M. J. (2006) · Nature Protocols · doi:10.1038/nprot.2006.170 · Cited by 1,115
Mfsd2a is a transporter for the essential omega-3 fatty acid docosahexaenoic acid
Nguyen, L. N., Ma, D., Shui, G., Wong, P., Cazenave-Gassiot, A., Zhang, X., Wenk, M. R., Goh, E. L. K., & Silver, D. L. (2014) · Nature · doi:10.1038/nature13241 · Cited by 1,048
Flagged first, then by citations
Cited by
Sorted by citations
Items 601–682 of 682
Pulikkan, J., Vasu, D. A., Deepthi, M., & Grace, T. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1010563 · Cited by 1
Alzheimer’s Disease Prevention and Treatment Using Herbal Agents
Brown, T. (2016) · Journal of Analytical & Pharmaceutical Research · doi:10.15406/japlr.2016.02.00027 · Cited by 1
Radhakrishnan, J., Baetiong, A., & Gazmuri, R. J. (2020) · Physiology & Behavior · doi:10.1016/j.physbeh.2020.112828 · Cited by 1
The ketogenic diet and healthy brain aging
Rogerson, G., & Preedy, V. R. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-817990-1.00049-4 · Cited by 1
A Review on Metabolic Dysfunction Hypothesis of Alzheimer's Disease
Majd, S. (2023) · International Journal of Research Publication and Reviews · doi:10.55248/gengpi.4.1223.123424 · Cited by 1
Shearer, T. S. (2017) · Wiley eBooks · doi:10.1002/9781119036722.ch15 · Cited by 1
Transporter-Mediated Drug DeliveryPreprint
Gyimesi, G., & Hediger, M. A. (2022) · Preprints.org · doi:10.20944/preprints202211.0062.v1 · Cited by 1
Expressional prerequisites for targeted drug delivery to the pathological brain
Helgudóttir, S. S. (2021) · VBN Forskningsportal (Aalborg Universitet) · doi:10.54337/aau424058297 · Cited by 1
Inhibition of MicroRNA-129-5p Promotes Neuroinflammation and Cognitive ImpairmentPreprint
Kaurani, L., Zhou, J., Pradhan, R., Schröder, S., Burkhardt, S., Schuetz, A.-L., Delalle, I., Rizzu, P., Heutink, P., Sananbenesi, F., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-3870232/v1 · Cited by 1
Role of Astrocytic Serine in Learning and Memory and its Implications in Alzheimer's Disease.
Maugard, M. (2018) · theses.fr (ABES) · doi:10.70675/2a0528d8zc687z43e6za9b4zfa45cdb5b6d9 · Cited by 1
Hernández-Garzón, E., Fernandez, A. M., Pérez‐Alvarez, A., Mederos, S., Pérez‐Domper, P., Bascuñana, P., de la Rosa, R. F., Delgado, M., Pozo, M. A., Miranda‐Vizuete, A., et al. (2015) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/023556
Genetic-Metabolic Disorders Presenting as Acute, but Reversible, Severe Epilepsies
Almuqbil, M., & Pearl, P. L. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-53088-0.00015-4
Nanotherapy for Alzheimer's Disease and Vascular Dementia: Targeting Senile EndotheliumPreprint
D'Arrigo, J. S. (2017) · SSRN Electronic Journal · doi:10.2139/ssrn.3041744
Investigating the role of the apelinergic system in glioblastoma
Venkatesh, V. S. (2018) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/wgtn.17134046
Blood-brain barrier disruption in a model of neonatal hypoxic-ischaemic encephalopathy
Goasdoué, K. (2019) · The University of Queensland · doi:10.14264/uql.2019.938
Supplemental Tables and Figures
Coppedge, M., Edgell, A. B., Knutsen, C. H., & Lindberg, S. I. (2022) · Cambridge University Press eBooks · doi:10.1017/9781009086974.017
Hirai, S. (2021) · The Brain & Neural Networks · doi:10.3902/jnns.28.93
Atherosclerosis and Vascular Imaging 2016
Henein, M. Y. (2017) · MDPI eBooks · doi:10.3390/books978-3-03842-433-8
White matter integrity of the frontal brain and its relevance for catatonia and executive function
Arinrad, S. (2021) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-8974
Diet in Brain Health and Neurological Disorders: Risk Factors and Treatments
Brandt, J. (2019) · MDPI eBooks · doi:10.3390/books978-3-03921-651-2
Nanotherapy for Early Dementia: Targeting Senile DementiaPreprint
D'Arrigo, J. S. (2017) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/3vysu
Nielsen, J. E. (2021) · VBN Forskningsportal (Aalborg Universitet) · doi:10.54337/aau455017331
Applications of Nanotechnology in Alzheimer’s Disease
Chountoulesi, M., Naziris, N., Gioran, A., Papagiannopoulos, A., Steele, B. R., Micha‐Screttas, M., Stavrinides, S. G., Hanias, M. P., Chondrogianni, N., Pispas, S., et al. (2022) · Springer eBooks · doi:10.1007/978-3-319-75479-6_16-1
Huang, S., Huang, X., Li, Z., Fu, F., & Yue, F. (2024) · Biophotonics and Immune Responses · doi:10.1117/12.3005107
Lowering glucose enhances BACE1 activity and Aβ generation in mouse brain slice culturesPreprint
Sheppard, O., Humphrey, R., Durrant, C. S., & Coleman, M. P. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.12.584616
Zhang, X., Wang, L., Li, Y., Liu, Z., Zhang, T., Yeqi, W. A. N. G., & Wang, G. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5149581
Nanotherapy for Early Dementia: Targeting Senile DementiaPreprint
D'Arrigo, J. S. (2017) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/3vysu_v1
Levin, O. S., & Гехаева, З. К. (2025) · The Clinician · doi:10.17650/1818-8338-2025-19-1-k744
Cerebrovascular p16INK4A expression induces cerebral small vessel disease-related phenotypes
Kawatani, K., Aikawa, T., Tabrizi, Z., Pan, Y., Ren, Y., Wang, N., Kurti, A., Nambara, T., Ikezu, C. C., Shue, F., et al. (2025) · Acta Neuropathologica Communications · doi:10.1186/s40478-025-02085-x
New genetic tools for central and peripheral vascular endotheliaPreprint
Xia, S., Ge, T., Song, R., Liu, Q., He, X., Shen, Y., Qiao, H., Qu, Y., Chen, J., Zhao, Z., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-7421061/v1
Self-citationMethyl-beta-cyclodextrin and myriocin alleviate blood–brain barrier impairment in septic rats
Akcan, U., Bakbak, H., Ayvaz, E., Atış, M., Yılmaz, C. U., Orhan, N., Kotil, T., Arıcan, N., Ahıshalı, B., & Kaya, M. (2025) · Histochemistry and Cell Biology · doi:10.1007/s00418-025-02421-1
Additional file 6 of JNK1 and JNK3: divergent functions in hippocampal metabolic-cognitive function
Busquets, O., Espinosa-Jiménez, T., Ettcheto, M., Olloquequi, J., Bullò, M., Carro, E., Cantero, J. L., Casadesús, G., Folch, J., Verdaguer, E., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19711265
Raut, S., Patel, R., & Al-Ahmad, A. J. (2021) · Figshare · doi:10.6084/m9.figshare.13545554
Qi, G., Tang, H., Gong, P., Liu, Y., He, C., Hu, J., Kang, S., Chen, L., & Qin, S. (2024) · Figshare · doi:10.6084/m9.figshare.27019232
[18F]FDG Revisited: A New Perspective on the Temporal Dynamics of Brain Glucose MetabolismPreprint
Hahn, A., Falb, P., Murgaš, M., Klug, S., Reed, M. B., Godbersen, G. M., de León, M. P., Milz, C., Hacker, M., Rujescu, D., et al. (2025) · Preprints.org · doi:10.20944/preprints202502.0892.v2
Ge, Y., Weng, Y., & Chen, Y. (2026) · Food and Chemical Toxicology · doi:10.1016/j.fct.2026.116005
Tamura, S., Shimbo, H., Aruga, N., Kawaguchi, M., Okado, H., Yasuda, Y., Miyaoka, Y., Sasakura, A., Matsuo, K., Nishihara, H., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.04.709430
Liang, X., Lohkamp, K. J., van den Hoek, A. M., Geenen, B., Verweij, V., Morrison, M. C., Kleemann, R., Kiliaan, A. J., Wiesmann, M., & Guardia, G. S. (2026) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2026.106539
Karmakar, A., Roycowdhury, P., Sengupta, P., & Mukhopadhyay, D. (2026) · International review of neurobiology · doi:10.1016/bs.irn.2026.02.007
Marqueurs périphériques de l'inflammation et déclin cognitif au cours de la maladie d'Alzheimer
Julian, A. (2018) · theses.fr (ABES) · doi:10.70675/0f58e0a1z28d9z40b7z886fz752caf42c261
Contribution de la voie Wnt dans la stabilité de la barrière hémato-encéphalique
Gueniot, F. (2019) · theses.fr (ABES) · doi:10.70675/7bb4438cz6983z40a4zb67bzd7cc0b7bb81c
Gu, Q., Xie, Y., Zhao, Z., Zhuang, Z., 杨淋清, Huang, H., Li, H., Pi, S., Chen, F., Gong, C., et al. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261435563
Self-citationGuo, Z., He, X., Ge, Y., Zhao, B. D., Huang, L.-Y., Chen, S., Fu, Y., Gao, P., Sheng, Z.-H., Huang, Y., et al. (2026) · European Journal of Neurology · doi:10.1111/ene.70558
Glycocalyx and basal lamina in neurological disorders
Nasrollahi, A., Yurchenco, P. D., & Yao, Y. (2026) · Matrix Biology · doi:10.1016/j.matbio.2026.102015
Brain shuttle target expression levels vary by individual, not by brain region, disease, age, or sexPreprint
Santa-Maria, A. R., Shahriar, S., Chandrasekhar, V., Luteijn, E., Horber, R., Hornstein, S., Tkachev, S. L., Levy, T. M., Gregoretti, I. V., Simpson, C. M., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.21.726908
Sudasinghe, K., & Hall, S. E. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1839995
Jangra, J., Mahindru, I., & Kumar, R. (2026) · International review of neurobiology · doi:10.1016/bs.irn.2026.05.005
Neurovascular coupling and energy substrate delivery in Alzheimer’s disease
Malviya, S., Saha, D., Kamble, A., Singh, D. R., Sundaram, S. M., & Devanathan, V. (2026) · International review of neurobiology · doi:10.1016/bs.irn.2026.05.001
Carrasco, M., Guzman, L., Barroso, E., Olloquequi, J., Cano, A., Ureña, J., Verdaguer, E., Prohens, R., Fortuna, A., Auladell, C., et al. (2026) · GeroScience · doi:10.1007/s11357-026-02321-9
Yang, X., Zhang, J., Yu, H., Zhao, Y., Hou, G., Wang, S., & Han, B. (2026) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(26)61099-0
Deng, L., Li, H., Yang, S., Chen, F., Qiao, J., 包慧中, Wang, X., Fang, S., Xu, B., & Tang, Z. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04654-1
Torres, A. P. C., Montesi, L., Loel, L., Yanovska, M., Venckute, J., Jessika, J., Wu, T., Benito‐Zarza, L., Cognetti, J. S., Fotouhi, O., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.21.733618
Ostovan, V. R., Gholami, S., SoukhakLari, R., & Moosavi, M. (2026) · Neurological Research · doi:10.1080/01616412.2026.2695820
Skike, C. E. V., Miller, L. R., Hernandez, S. F., Hussong, S. A., Makhlouf, H., Muppala, A., DeRosa, N., Jahrling, J. B., Dineley, K. T., & Galván, V. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.23.733858
Non‐Alzheimer Aβ deposits in the human CNS : Implications with hypoxia and related conditions
Karlovich, E., Priemer, D. S., Rhodes, C. H., Perl, D. P., Tanji, K., & Goldman, J. E. (2026) · Brain Pathology · doi:10.1111/bpa.70120
Clark, K. L., Mecca, S., Almaoui, E., Bossardet, O. L., Holden, J. M., Calkins, D. J., & Wareham, L. K. (2026) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2026.1870679
Olayemi, O. E., Anthony, E. C., Edema, V. B., & Oyesola, O. (2026) · Advances in Biomedical and Health Sciences · doi:10.4103/abhs.abhs_111_25
Tarawneh, R. (2026) · Biomedicines · doi:10.3390/biomedicines14081794
Yang, Q., Zhang, J., Dao, Y., He, Z., Lu, R., Jaman, R., Wu, Y., Liu, S., Zhang, C., Zhang, Z., et al. (2026) · iScience · doi:10.1016/j.isci.2026.117147
Blood–Brain Barrier and Its Overlooked Proteoglycan Regulators
Champagne, R., Myers, J., Pearson, H., Wenke, K., Varghese, D., & Purushothaman, A. (2026) · Biomolecules · doi:10.3390/biom16111559
Targeting GLUTs in Cancer: Mechanisms, Combination Strategies, and Translational Challenges
Shi, M.-N., Yang, D.-F., Chu, T., Zheng, D.-Y., & Ma, W. (2026) · Current Medical Science · doi:10.1007/s11596-026-00245-1
Solute carrier membrane transporters: emerging targets in CNS disorders
Law, Y. K., Glück, S., Girardi, E., Bensimon, A., Angermayr, S. A., & Superti‐Furga, G. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01513-4
Fagundes, C. P., & Argueta, D. L. (2026) · SSRN Electronic Journal · doi:10.2139/ssrn.7381184
Identification and Validation of the Nrf2/Slc2a1 Axis in Alzheimer’s Disease
Luo, Y., Deng, J., Loh, Y., Lu, H., Wang, N., Tang, C., & Zhang, B. (2026) · Genes · doi:10.3390/genes17091081
Méndez, F., Cisternas, P., Ormazabal, P., Gherardelli, C., Frangópulos, M., Mansilla, A., & Inestrosa, N. C. (2026) · Pharmaceuticals · doi:10.3390/ph19091489
Proteomics Reveals Blood−Brain Barrier Membrane Protein Remodeling in Amyloid-β Pathology
Hyvärinen, J., Todorovska, R., Palacios, M. D. P., Gynther, M., Afonin, A., Lehtonen, M., Auriola, S., Saveleva, L., Kanninen, K. M., Fricker, G., et al. (2026) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6c00935
Singh, A., Bhukta, S., Mishra, D., Palei, N. N., Verma, A., & Mohapatra, L. (2026) · AAPS PharmSciTech · doi:10.1208/s12249-026-03563-8
Exercise, Glucose and Lactate Metabolism in Mild Cognitive Impairment: A Narrative Review
Kim, D. H., Moon, H. Y., & 이민철 (2026) · International Journal of Sports Medicine · doi:10.1055/a-2972-5240
Zhu, Y., Yang, D., chen, J., wang, Q., Xiong, W., wang, J., chen, H., Verkhratsky, A., & Yi, C. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.30.755839
Diabetes‐Associated Cognitive Impairment: Pathophysiology and Emerging Therapies
Corbali, O., Menon, P., Corbali, H. I., Jagannathan, R., & Levey, A. I. (2026) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.70487
León‐Arcia, K., Martínez-Orozco, H., Crespo, M., Díaz-Cintra, S. Y., & Soto-Rojas, L. O. (2026) · Journal of Molecular Neuroscience · doi:10.1007/s12031-026-02610-0
Physical exercise: a multi-target strategy for the prevention and treatment of Alzheimer’s disease
佟乌云 (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1876075
Developing precision nanoparticle-based drug delivery systems for Alzheimer's disease therapy
Shan, Q., Zheng, W., Yao, W., Bai, Y., Ding, W., Wang, J., & Bai, F. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.103789
Gao, C., Shi, R., Jiang, X., Chai, H., & He, X. (2026) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2026.126237
Deciphering the neuroprotective signaling of SGLT2 inhibitors in Alzheimer's disease
Kamihara, T., Kato, R., Morisaki, A., Kaneko, S., Omura, T., & Shimizu, A. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261502860
Liang, R., Wang, B., Ke, Z., & Wang, S. (2026) · Brain Sciences · doi:10.3390/brainsci16111190
Brain glucose metabolism and blood brain barrier permeability in Alzheimer’s disease continuum
Ricci, F., Motta, C., Bonomi, C. G., Bernocchi, F., Poli, M., Koch, G., Chiaravalloti, A., & Martorana, A. (2026) · Aging · doi:10.18632/aging.206393
Metadata
- Authors
- Winkler, E. A., Nishida, Y., Sagare, A. P., Rege, S. V., Bell, R. D., Perlmutter, D., Sengillo, J. D., Hillman, S., Kong, P., Nelson, A. R., Sullivan, J. S., Zhao, Z., Meiselman, H. J., Wenby, R. B., Soto, J., Abel, E. D., Makshanoff, J., Zuniga, E., De Vivo, D. C., & Zlokovic, B. V.
- Affiliations
- University of Southern California (US)
- Tokyo Medical and Dental University (JP)
- University of Rochester Medicine (US)
- University of Iowa (US)
- ORCID
- Venue
- Nature Neuroscience
- Published
- 2015-03-02
- Volume
- 18
- Issue
- 4
- Pages
- 521-530
- ISSN
- 1097-6256 (ISSN-L)
- 1546-1726
- PMC
- PMC4734893
- OpenAlex
- W1974266381
- Cited by
- 689
- References
- 63
- Citations by year
- 2026: 65 · 2025: 72 · 2024: 65 · 2023: 62 · 2022: 79 · 2021: 78 · 2020: 62 · 2019: 49 · 2018: 52 · 2017: 47 · 2016: 38 · 2015: 20
- FWCI
- 27.97
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- University of Southern California
- National Institutes of Health
- National Institute on Aging (R01AG023084, R01AG039452, R37AG023084, AG039452, RF1AG039452, AG023084)
- National Heart, Lung, and Blood Institute (U01HL087947)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK092065)
- National Institute of Neurological Disorders and Stroke (NS034467, R37NS034467, R01NS034467)
- Topics
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
- Keywords
- GLUT1, Alzheimer's disease, blood-brain barrier, brain endothelium, amyloid-beta, amyloid-beta clearance, glucose transport, neurodegeneration, cerebrovascular dysfunction, cognitive impairment, therapeutic target
- MeSH terms
- Alzheimer Disease, Animals, Blood-Brain Barrier, Cerebrovascular Circulation, Disease Models, Animal, Endothelium, Vascular, Mice, Inbred C57BL, Mice, Transgenic, Amyloid beta-Peptides, Glucose Transporter Type 1, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
